Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Trial of Ruxolitinib in Combination With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma.

NCT06991101 is registered in ClinicalTrials.gov with Baptist Health South Florida as lead sponsor.

NCT NCT06991101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06991101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Trial of Ruxolitinib in Combination With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma.
Lead sponsor
Baptist Health South Florida
Phase
Phase 2
Overall status
Recruiting
Start date
December 3, 2025
Completion date
December 31, 2030
Enrollment
190 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, glioblastoma, glioblastoma multiforme, glioblastoma multiforme of brain, glioblastoma multiforme, adult, mgmt-methylated glioblastoma, mgmt-unmethylated glioblastoma